Recurrent Wheeze in Healthy Preterm Infants
(Ivanhoe Newswire) – Researchers out of the University Medical Center Utrecht performed a multicenter, double-blind, randomized trial to determine the potential causal role of respiratory syncytial virus (RSV) infection in the pathogenesis of wheezing illness during the first year of life, using the commercial monoclonal antibody palivizumab against RSV.
Severe RSV bronchiolitis has been associated with an increase in multiple events of early wheezing, asthma, and possibly allergic sensitization later in life. The pathogenesis of recurrent wheeze after RSV infection is still not understood. To address this issue, researchers enrolled preterm infants in pediatric departments of one university and 15 regional hospitals in the Netherlands from April 2008 until December 2010. Researchers found that the administration of palivizumab for RSV prevention reduced the total number of wheezing days in the first year of life. The post-prophylaxis effect of RSV prevention on wheezing illness is evidence that RSV infection is an important mechanism in the pathogenesis of wheezing during the first year of life among late preterm infants.
For more information, go to: http://www.nejm.org/doi/full/10.1056/NEJMoa1211917
SOURCE: New England Journal of Medicine, May 2013
Click Here for a free weekly email with Ivanhoe's latest Medical Breakthroughs.